GSK, Theravance report completion of Relovair studies in COPD and asthma – Pharmaceutical Business Review


Visit Bulgaria

GSK, Theravance report completion of Relovair studies in COPD and asthma
Pharmaceutical Business Review
GlaxoSmithKline (GSK) and Theravance have announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair used to treat chronic obstructive pulmonary disease (COPD) and asthma.
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies MarketWatch (press release)
Theravance Falls Most in 3 Years After Glaxo Drug FailsBusinessWeek
Glaxo on the slide after trials setback for asthma drugEvening Standard
Visit Bulgaria –TheStreet.com –Wall Street Journal (India)
all 64 news articles »

View full post on asthma – Google News

A review on herbal antiasthmatics.

A review on herbal antiasthmatics.

Orient Pharm Exp Med. 2011 Aug;11(2):77-90

Authors: Mali RG, Dhake AS

Abstract
In traditional systems of medicine, many plants have been documented to be useful for the treatment of various respiratory disorders including asthma. In the last two decades the use of medicinal plants and natural products has been increased dramatically all over the world. Current synthetic drugs used in pharmacotherapy of asthma are unable to act at all the stages and targets of asthma. However some herbal alternatives employed in asthma are proven to provide symptomatic relief and assist in the inhibition of disease progression also. The herbs have shown interesting results in various target specific biological activities such as bronchodilation, mast cell stabilization, anti-anaphylactic, anti-inflammatory, anti-spasmodic, anti-allergic, immunomodulatory and inhibition of mediators such as leukotrienes, lipoxygenase, cyclooxygenase, platelet activating, phosphodiesterase and cytokine, in the treatment of asthma. This paper is an attempt to classify these pharmacological and clinical findings based on their possible mechanism of action reported. It also signifies the need for development of polyherbal formulations containing various herbs acting at particular sites of the pathophysiological cascade of asthma for prophylaxis as well as for the treatment of asthma.

PMID: 22207824 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

A clinical review of different formulations of Vasa (Adhatoda vasica) on Tamaka Shwasa (asthma).

A clinical review of different formulations of Vasa (Adhatoda vasica) on Tamaka Shwasa (asthma).

Ayu. 2010 Oct;31(4):520-4

Authors: Gupta A, Prajapati PK

Abstract
Vasa (Adhatoda vasica Linn.) is a well known and easily available drug in almost all the seasons. Easy availability of any drug gains popularity among physicians as well as pharmaceuticals and this is the reason why almost every Kalpana of Vasa is found described in the Ayurvedika text. The different dosage forms of Vasa like Kvatha, Avaleha, Sneha, and Sandhana have been used for the treatment of Shwasa Roga. A number of research studies have been performed on different formulations of Vasa and its effect on Shwasa Roga. Therefore, a review study has been carried out on the Vasa extract, Vasa Avaleha (prepared from Svarasa and Kvatha), Vasa Ghrita, Vasarishta, and Vasakasava on Shwasa Roga, to know which formulation is better. It was found in the review that Vasa Ghana, Vasa Ghrita (1), and Vasa Avaleha have shown good results on Tamaka Shwasa.

PMID: 22048552 [PubMed – in process]

View full post on pubmed: asthma

Merck Dulera shows efficacy in COPD treatment – Pharmaceutical Business Review

Merck Dulera shows efficacy in COPD treatment
Pharmaceutical Business Review
Dulera Inhalation Aerosol, which is used to treat asthma combines mometasone furoate, an inhaled corticosteroid, and formoterol fumarate, a long-acting beta2-agonist. The two 26-week, multicenter, double-blind, placebo controlled trials comprising 2251
Merck Announces Presentation of Phase III Investigational Studies Evaluating MarketWatch (press release)

all 12 news articles »

View full post on asthma – Google News

Kissei funds for MediciNova asthma drug development – Pharmaceutical Business Review

Kissei funds for MediciNova asthma drug development
Pharmaceutical Business Review
Kissei Pharmaceutical is funding $2.5m to support further clinical development of MediciNova's MN-221 to treat acute exacerbations of asthma or chronic obstructive pulmonary disease (COPD). As per the license agreenent signed between the two companies
MediciNova to Receive $2.5 Million Payment From Kissei Pharmaceutical Co. Ltd MarketWatch (press release)
Kissei To Pay MediciNova $2.5 Mln To Support Clinical Development Of MN-221RTT News
MediciNova Inc expects USD2.5m from Kissei Pharmaceutical Co Ltd for MN-221 Middle East North Africa Financial Network

all 10 news articles »

View full post on asthma – Google News

US to phase out OTC asthma inhalers citing environmental concerns – Pharmaceutical Business Review

US to phase out OTC asthma inhalers citing environmental concerns
Pharmaceutical Business Review
The United States Food and Drug Administration (FDA) announced that over-the-counter (OTC) asthma inhaler, Primatene Mist, containing chlorofluorocarbons (CFCs) will be taken off the US market from 31 December. The CFCs present in the product deplete
Teva Respiratory Provides Resources for Patients Impacted by PRIMATENE(R) MIST MarketWatch (press release)

all 13 news articles »

View full post on asthma – Google News

Gene Variant Could Explain Why Asthma Treatment Often Fails – MIT Technology Review


Los Angeles Times

Gene Variant Could Explain Why Asthma Treatment Often Fails
MIT Technology Review
A new study has revealed a genetic variant among asthma patients who don't respond well to steroid inhalers, the main treatment for the disease. The discovery could lead to a DNA test that could identify such patients early on,
Gene could explain why asthma treatments fail someReuters
What asthma means for those who have itKansas.com
Gene variant associated with reduced response to asthma inhalersLos Angeles Times
MedPage Today –MedCity News –HealthCanal.com
all 55 news articles »

View full post on asthma – Google News